Orchid Pharma Poised for Revenue Surge as Russia Licensing Pact Fuels Exblifep Outlook

Orchid Pharma Poised for Revenue Surge as Russia Licensing Pact Fuels Exblifep Outlook​

Orchid Pharma shares are set to remain in keen focus on July 8 after the company secured an exclusive licensing and supply agreement. This significant partnership involves Pharmasyntez JSC for the commercialization of Exblifep (cefepime/enmetazobactam) within Russia. The deal provides a strong revenue catalyst, leveraging the drug's established global standing in the anti-infective market.

Details of the Exclusive Market Agreement​

Under the terms of the agreement, Pharmasyntez will take on the exclusive rights to register and market Exblifep across Russia. This is contingent upon regulatory approval from the country's Ministry of Health. Crucially, Orchid Pharma remains responsible for manufacturing and supplying the finished dosage form of the novel drug.

The partnership carries a substantial potential revenue opportunity estimated at around $178 million over the initial ten years. This projection is driven by the unmet clinical demand in Russia and expected large-scale hospital procurement commitments.

Significance of Exblifep​

Exblifep is an advanced carbapenem-sparing antibiotic designed for critical infection management. It is specifically indicated to treat complicated urinary tract infections (cUTI). The drug is also vital in treating hospital-acquired and ventilator-associated bacterial pneumonia (HAP/VAP) caused by Gram-negative bacterial pathogens.

The efficacy of Exblifep is backed by major international regulatory bodies. It has already received approvals from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Furthermore, it is included in treatment guidelines issued by IDSA and EUCAST.

Expert View and Market Performance​

Manish Dhanuka, Managing Director of Orchid Pharma, commented on the development's impact. He stated that the collaboration with Pharmasyntez will significantly expand Exblifep’s access in Russia. This expansion is supported by leveraging Pharmasyntez’s robust presence within the nation's hospital procurement network.

In the previous trading session, the stock closed at Rs 926.65, recording a decline of Rs 5.95 or 0.64 percent. The company currently boasts a market capitalization standing at Rs 4,699.89 crore.

Stock Performance and Valuation Metrics​

The stock has demonstrated strong upward movement recently, having surged by 78 percent over the last three months. Its current valuation remains significantly above its historical low point. Orchid Pharma's share price touched a 52-week high of Rs 1,096.40. The company also recorded a 52-week low of Rs 471.30 on March 30, 2026.

Currently, the stock is trading at levels that are 15.48 percent below its 52-week high. However, it remains substantially elevated compared to the lowest point recorded.